Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
BMC Med
2015 May 09;13:108. doi: 10.1186/s12916-015-0350-3.
Show Gene links
Show Anatomy links
Accuracy of microRNAs as markers for the detection of neck lymph node metastases in patients with head and neck squamous cell carcinoma.
de Carvalho AC
,
Scapulatempo-Neto C
,
Maia DC
,
Evangelista AF
,
Morini MA
,
Carvalho AL
,
Vettore AL
.
???displayArticle.abstract???
BACKGROUND: The presence of metastatic disease in cervical lymph nodes of head and neck squamous cell carcinoma (HNSCC) patients is a very important determinant in therapy choice and prognosis, with great impact in overall survival. Frequently, routine lymph node staging cannot detect occult metastases and the post-surgical histologic evaluation of resected lymph nodes is not sensitive in detecting small metastatic deposits. Molecular markers based on tissue-specific microRNA expression are alternative accurate diagnostic markers. Herein, we evaluated the feasibility of using the expression of microRNAs to detect metastatic cells in formalin-fixed paraffin-embedded (FFPE) lymph nodes and in fine-needle aspiration (FNA) biopsies of HNSCC patients.
METHODS: An initial screening compared the expression of 667 microRNAs in a discovery set comprised by metastatic and non-metastatic lymph nodes from HNSCC patients. The most differentially expressed microRNAs were validated by qRT-PCR in two independent cohorts: i) 48 FFPE lymph node samples, and ii) 113 FNA lymph node biopsies. The accuracy of the markers in identifying metastatic samples was assessed through the analysis of sensitivity, specificity, accuracy, negative predictive value, positive predictive value, and area under the curve values.
RESULTS: Seven microRNAs highly expressed in metastatic lymph nodes from the discovery set were validated in FFPE lymph node samples. MiR-203 and miR-205 identified all metastatic samples, regardless of the size of the metastatic deposit. Additionally, these markers also showed high accuracy when FNA samples were examined.
CONCLUSIONS: The high accuracy of miR-203 and miR-205 warrant these microRNAs as diagnostic markers of neck metastases in HNSCC. These can be evaluated in entire lymph nodes and in FNA biopsies collected at different time-points such as pre-treatment samples, intraoperative sentinel node biopsy, and during patient follow-up. These markers can be useful in a clinical setting in the management of HNSCC patients from initial disease staging and therapy planning to patient surveillance.
???displayArticle.pubmedLink???
25956054
???displayArticle.pmcLink???PMC4493814 ???displayArticle.link???BMC Med
Figure 1. Schematic representation of lymph nodes sectioning protocol for immunohistochemistry (solid line) and molecular (dotted line) analyses. (A) Non-metastatic lymph nodes: all sections at different levels were used for RNA extraction and subsequent molecular analysis (arrows). (B) Metastatic lymph nodes: only sections of the positive level at IHC analysis were used for RNA extraction and subsequent molecular analysis (arrow). The leftover material (regions marked with “*”) removed from each interval of 50 μm was collected and used in the analysis of the leftover material.
Figure 2. Immunohistochemistry staining for cytokeratins (M3515, clone AE1/AE3, Dako) in histologically negative lymph nodes of HNSCC patients. (A) Lymph node without evidence of metastases. (B) Lymph node with macrometastases. (C) Lymph node with micrometastases. (D) Lymph node with isolated tumor cells. A, B, and C: 40× magnification; D: 400× magnification.
Figure 4. ROC (Receiver Operating Characteristic) curves obtained for microRNAs miR-200a, miR-200c, miR-203, and miR-205 in the FFPE validation set.
Figure 5. Expression profile of miR-200a, miR-200c, miR-203, and miR-205 in lymph node samples containing macrometastases (Ma; n = 18), micrometastases/isolated tumor cells (Mi and isolated tumor cells; n = 7), or in non-metastatic lymph node specimens (NM; n = 13). The Y-axis shows the log10 fold-change of the relative expression (2-ΔΔCt). The P value (Mann–Whitney) from each comparison is provided. The dotted line indicates the cutoff adopted according to the Youden index (value in which the difference between sensitivity and 1-specificity is maximum) obtained from the ROC curves analysis. The horizontal line indicated the median of fold-change values for each group.
Figure 6. Expression profile of miR-203 and miR-205 in FNA biopsies from lymph nodes classified as positive (FNA+) or negative (FNA–) according to (A) cytological diagnostic (FNA+: n = 42; FNA–; n = 71) and (B) histological diagnostic (FNA+: n = 45; FNA–; n = 68). The Y-axis shows the log10 fold-change of the relative expression (2-ΔΔCt). The P value (Mann–Whitney) from each comparison is provided. The dotted line indicates the 10-fold cutoff adopted.
Figure 7. Receiver Operating Characteristic curves obtained for microRNAs miR-203 and miR-205 in in FNA biopsies from lymph nodes classified as positive (FNA+) or negative (FNA–) according to (A) cytological diagnostic and (B) histological diagnostic.
Ambrosch,
Detection of nodal micrometastases in head and neck cancer by serial sectioning and immunostaining.
1996, Pubmed
Ambrosch,
Detection of nodal micrometastases in head and neck cancer by serial sectioning and immunostaining.
1996,
Pubmed
Barrera,
Detection of occult cervical micrometastases in patients with head and neck squamous cell cancer.
2003,
Pubmed
Bartel,
MicroRNAs: genomics, biogenesis, mechanism, and function.
2004,
Pubmed
Becker,
Molecular assay to detect metastatic head and neck squamous cell carcinoma.
2004,
Pubmed
Berner,
Fine needle aspirations in oncology.
2011,
Pubmed
Carvalho,
Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database.
2005,
Pubmed
Childs,
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma.
2009,
Pubmed
Corbi,
Comparative expression of a set of genes to an internal housekeeping control in CDNA amplified and not amplified by PolyAPCR in non-Hodgkin's lymphoma samples obtained from fine-needle aspiration cytology.
2010,
Pubmed
Dias,
Elective neck dissection versus observation in stage I squamous cell carcinomas of the tongue and floor of the mouth.
2001,
Pubmed
Elsheikh,
Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma.
2006,
Pubmed
Enepekides,
Occult cervical metastases: immunoperoxidase analysis of the pathologically negative neck.
1999,
Pubmed
Ferlay,
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
2010,
Pubmed
Ferlito,
Neck dissection: past, present and future?
2006,
Pubmed
Ferlito,
Elective and therapeutic selective neck dissection.
2006,
Pubmed
Ferracin,
MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.
2011,
Pubmed
Ferris,
Intraoperative qRT-PCR for detection of lymph node metastasis in head and neck cancer.
2011,
Pubmed
Fletcher,
Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205.
2008,
Pubmed
Hamakawa,
Histological study on pN upgrading of oral cancer.
2000,
Pubmed
He,
MicroRNAs: small RNAs with a big role in gene regulation.
2004,
Pubmed
Heilo,
Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma.
2011,
Pubmed
Hong,
RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis.
2006,
Pubmed
Hui,
Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas.
2010,
Pubmed
Kligerman,
Supraomohyoid neck dissection in the treatment of T1/T2 squamous cell carcinoma of oral cavity.
1994,
Pubmed
Kuntz,
Impact of neck dissection on quality of life.
1999,
Pubmed
Leemans,
Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor.
1994,
Pubmed
Lim,
Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue.
2004,
Pubmed
Livak,
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
2001,
Pubmed
Lu,
MicroRNA expression profiles classify human cancers.
2005,
Pubmed
Nagadia,
miRNAs in head and neck cancer revisited.
2013,
Pubmed
Olson,
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
2009,
Pubmed
Rhee,
The significance of immunohistochemically demonstrated nodal micrometastases in patients with squamous cell carcinoma of the head and neck.
2002,
Pubmed
Rodrigo,
Management of the clinically negative neck in early-stage head and neck cancers after transoral resection.
2011,
Pubmed
Rosenfeld,
MicroRNAs accurately identify cancer tissue origin.
2008,
Pubmed
Ruopp,
Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection.
2008,
Pubmed
Salazar,
miRNAs in human papilloma virus associated oral and oropharyngeal squamous cell carcinomas.
2014,
Pubmed
Salazar,
A novel saliva-based microRNA biomarker panel to detect head and neck cancers.
2014,
Pubmed
Schiefke,
Function, postoperative morbidity, and quality of life after cervical sentinel node biopsy and after selective neck dissection.
2009,
Pubmed
Shah,
Cervical lymph node metastases--diagnostic, therapeutic, and prognostic implications.
1990,
Pubmed
Shah,
Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract.
1990,
Pubmed
Shores,
Clinical evaluation of a new molecular method for detection of micrometastases in head and neck squamous cell carcinoma.
2004,
Pubmed
Takes,
Staging of the neck in patients with head and neck squamous cell cancer: imaging techniques and biomarkers.
2004,
Pubmed
Taylor,
Head and neck cancer.
2001,
Pubmed
Thomsen,
Sentinel lymph nodes in cancer of the oral cavity -- isolated tumour cells.
2005,
Pubmed
Thomsen,
Sentinel lymph nodes in cancer of the oral cavity: is central step-sectioning enough?
2007,
Pubmed
Tu,
Upper neck (level II) dissection for N0 neck supraglottic carcinoma.
1999,
Pubmed
Wei,
Management of the N0 neck--reference or preference.
2006,
Pubmed
Woolgar,
Micrometastasis in oral/oropharyngeal squamous cell carcinoma: incidence, histopathological features and clinical implications.
1999,
Pubmed
van Diest,
Pathologic analysis of sentinel lymph nodes.
2001,
Pubmed
